Related Experiment Video
Updated: Jul 29, 2025
Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
Antiplatelet drugs do not protect from platelet-leukocyte aggregation in coronary artery disease
Christian Schulte1, Luise Pieper2, Maike Frye3
1Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Centre of Cardiovascular Research (DZHK), Partner Site Hamburg, Luebeck, Kiel, Hamburg, Germany.
Insights
Platelet-leukocyte aggregates (PLAs) are elevated in coronary artery disease (CAD) patients, independent of platelet activation. Current antiplatelet therapies do not reduce PLA formation or basal platelet degranulation in CAD.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Immunology
Background:
- Coronary artery disease (CAD) is a major cause of mortality.
- Platelet-leukocyte aggregates (PLAs) are implicated in CAD pathophysiology.
- PLAs may serve as diagnostic markers or therapeutic targets in CAD.
Purpose of the Study:
- Characterize PLAs in CAD patients.
- Investigate the association between PLA levels and CAD diagnosis.
- Assess platelet activation and degranulation in CAD patients and controls.
- Analyze the effect of antiplatelet treatments on PLAs and platelet function.
Main Methods:
- Recruited patients with and without CAD.
- Utilized flow cytometry to assess PLAs, platelet activation, and degranulation.
- Compared measurements between CAD patients and controls.
- Evaluated the impact of antiplatelet therapy.
Main Results:
- CAD patients exhibited higher circulating PLAs and basal platelet degranulation than controls.
- No significant correlation was found between PLA levels and platelet degranulation.
- Antiplatelet therapy did not reduce PLA or degranulation levels in CAD patients.
Conclusions:
- PLA formation in CAD may be independent of platelet activation or degranulation.
- Current antiplatelet treatments appear ineffective in preventing basal platelet degranulation and PLA formation in CAD.
- Further research is needed to understand PLA mechanisms and develop targeted therapies.
Background:
Despite advances in cardiovascular medicine, coronary artery disease (CAD) remains a leading cause of mortality. Among the pathophysiological features of this condition, platelet-leukocyte aggregates (PLAs) require further attention, either as diagnostic/prognostic disease markers or as potential interventional targets.
Objectives:
In this study, we characterized PLAs in patients with CAD. Primarily, we investigated the association of PLA levels with CAD diagnosis. In addition, the basal levels of platelet activation and degranulation were assessed in patients with CAD and controls, and their correlation with PLA levels was analyzed. Finally, the effect of antiplatelet treatments on circulating PLA numbers, basal platelet activation, and degranulation was studied in patients with CAD.
Methods:
Participants were recruited at the Department of Cardiology of the University Heart and Vascular Centre Hamburg Eppendorf. Among patients admitted with severe chest pain, the diagnosis of CAD was made angiographically, and patients without CAD were used as controls. PLAs, platelet activation, and platelet degranulation were assessed by flow cytometry.
Results:
Circulating PLAs and basal platelet degranulation levels were significantly higher in patients with CAD than in controls. Surprisingly, there was no significant correlation between PLA levels and platelet degranulation (or any other measured parameter). In addition, patients with CAD on antiplatelet therapy did not display lower PLA or platelet degranulation levels compared with those in controls.
Conclusion:
Overall, these data suggest a mechanism of PLA formation that is independent of platelet activation or degranulation and highlights the inefficiency of current antiplatelet treatments for the prevention of basal platelet degranulation and PLA formation.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Coronary Artery Disease II: Pathophysiology
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...